Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents
Grand-DES
1 other identifier
observational
17,286
1 country
37
Brief Summary
The objective of this study is to evaluate the long-term efficacy and safety of coronary stenting with the various types of drug-eluting stents (DES) and to determine clinical device and procedural success during commercial use of DES in the real world. The investigators will compare EES (Xience V/Promus and Xience Prime), SES (Cypher), ZES (Resolute Integrity, Endeavor Resolute, Endeavor), and BES (Biomatrix, Biomatrix Flex, and Nobori).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2008
Longer than P75 for all trials
37 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
November 30, 2017
CompletedFirst Submitted
Initial submission to the registry
April 15, 2018
CompletedFirst Posted
Study publicly available on registry
April 24, 2018
CompletedApril 27, 2026
April 1, 2026
9.6 years
April 15, 2018
April 22, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Target lesion failure
A composite of cardiac death, target-vessel myocardial infarction, and clinically-driven target lesion revascularization
36 months
Secondary Outcomes (9)
Patient-oriented composite outcome
36 months
All-cause death
36 months
Cardiac death
36 months
All-cause myocardial infarction
36 months
Target-vessel myocardial infarction
36 months
- +4 more secondary outcomes
Study Arms (5)
HOST-BIOLIMUS-Korea-3000
Active prospective registration of patients receiving biodegradable polymer-coated biolimus-eluting stents (BP-BES; Biomatrix, Biomatrix Flex, Nobori)
EXCELLENT-PRIME
Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents (DP-EES; Xience Prime)
EXCELLENT Prospective cohort
Active prospective registration of patients receiving durable polymer-coated everolimus-eluting stents and sirolimus-eluting stents (Xience V/Promus; Cypher)
HOST-RESOLINTE
Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES-RI; Resolute Integrity)
RESOLUTE-Korea
Active prospective registration of patients receiving durable polymer-coated zotarolimus-eluting stents (DP-ZES; Endeavor; Resolute)
Interventions
Biodegradable polymer-coated biolimus-eluting stents
Durable polymer-coated everolimus-eluting stents
Durable polymer-coated zotarolimus-eluting stents
Durable polymer-coated everolimus-eluting stents; Sirolimus-eluting stents
Durable polymer-coated zotarolimus-eluting stents
Eligibility Criteria
A total of 17,286 patients derived from a population of patients receiving percutaneous coronary intervention for ischemic heart disease will be enrolled in the present registry.
You may qualify if:
- The patient agrees to participate in this study by signing the informed consent form.
- Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (37)
Wonju Severance Christian Hospital
Wŏnju, Gangwon-do, South Korea
Sejong General Hospital
Bucheon-si, Gyeonggi-do, South Korea
Seoul National University Hospital
Seoul, Jongno-gu, 03080, South Korea
Hallym University Sacred Heart Hospital
Anyang, South Korea
Kosin University Gospel Hospital
Busan, South Korea
Dankook University Hospital
Cheonan, South Korea
Soon Chun Hyang University Hospital Cheonan
Cheonan, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Chonnam National University Hospital
Gwangju, South Korea
Gwangju Christian Hospital
Gwangju, South Korea
Kwangju Veterans Hospital
Gwangju, South Korea
Chonbuk National University Hospital
Iksan, South Korea
Wonkwang University Hospital
Iksan, South Korea
Inje University Ilsan Paik Hospital
Ilsan, South Korea
National Health Insurance Corporation Ilsan Hospital
Ilsan, South Korea
Inha University Hospital
Inchon, South Korea
Chungbuk National University Hospital
Jeonju, South Korea
Presbyterian Medical Center
Jeonju, South Korea
Gyeongsang National University Hospital
Jinju, South Korea
Inje University Pusan Paik Hospital
Pusan, South Korea
Pusan National University Hospital
Pusan, South Korea
Bundang CHA Medical Center
Seongnam, South Korea
Seoul National University Bundang Hospital
Seongnam, South Korea
Ewha Womans University Medical Center Mokdong Hospital
Seoul, South Korea
Gangbuk Samsung Hospital
Seoul, South Korea
Gangnam Severance Hospital
Seoul, South Korea
Hallym University Kangdong Sacred Heart Hospital
Seoul, South Korea
Hanyang University Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Kyung Hee University Hospital at Gangdong
Seoul, South Korea
Kyung Hee University Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul Boramae Hospital
Seoul, South Korea
Soonchunhyang University Hospital
Seoul, South Korea
Yonsei University Medical Center
Seoul, South Korea
St. Carollo Hospital
Suncheon, South Korea
Uijeongbu St. Mary's Hospital
Uijeongbu-si, South Korea
Related Publications (6)
Lee HS, Park KW, Kang J, Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Sarcopenia Index as a Predictor of Clinical Outcomes in Older Patients with Coronary Artery Disease. J Clin Med. 2020 Sep 27;9(10):3121. doi: 10.3390/jcm9103121.
PMID: 32992530RESULTPark J, Han JK, Kang J, Chae IH, Lee SY, Choi YJ, Rhew JY, Rha SW, Shin ES, Woo SI, Lee HC, Chun KJ, Kim D, Jeong JO, Bae JW, Yang HM, Park KW, Kang HJ, Koo BK, Kim HS. The Clinical Impact of beta-Blocker Therapy on Patients With Chronic Coronary Artery Disease After Percutaneous Coronary Intervention. Korean Circ J. 2022 Jul;52(7):544-555. doi: 10.4070/kcj.2021.0395. Epub 2022 Apr 4.
PMID: 35491482DERIVEDHwang D, Park J, Yang HM, Yang S, Kang J, Han JK, Park KW, Kang HJ, Koo BK, Kim HS. Angiographic complete revascularization versus incomplete revascularization in patients with diabetes mellitus. Cardiovasc Diabetol. 2022 Apr 19;21(1):56. doi: 10.1186/s12933-022-01488-7.
PMID: 35439958DERIVEDKim M, Park KW, Lee HS, Ki YJ, Kang J, Kim CH, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents. Catheter Cardiovasc Interv. 2021 Sep;98(3):E332-E341. doi: 10.1002/ccd.29682. Epub 2021 Apr 5.
PMID: 33817960DERIVEDKang J, Park KW, Lee HS, Zheng C, Rhee TM, Ki YJ, Chang M, Han JK, Yang HM, Kang HJ, Koo BK, Kim HS. Relative Impact of Clinical Risk Versus Procedural Risk on Clinical Outcomes After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2021 Feb;14(2):e009642. doi: 10.1161/CIRCINTERVENTIONS.120.009642. Epub 2021 Feb 5.
PMID: 33541106DERIVEDZheng C, Kang J, Yang HM, Han JK, Park KW, Kang HJ, Koo BK, Kim HS. Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Myocardial Infarction in the Presence of Intracoronary Thrombus: An Analysis From the Grand Drug-eluting Stent Registry. Clin Ther. 2020 May;42(5):954-958.e6. doi: 10.1016/j.clinthera.2020.02.022. Epub 2020 Mar 26.
PMID: 32224030DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Hyo-Soo Kim, MD, PhD
Seoul National University Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Investigator
Study Record Dates
First Submitted
April 15, 2018
First Posted
April 24, 2018
Study Start
April 1, 2008
Primary Completion
November 1, 2017
Study Completion
November 30, 2017
Last Updated
April 27, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share